White to off-white to light yellow powder or crystals
-92.0 to -98.0° (c=1.4, H2O)
Store long-term at -20°C
Water: 20mg/mL; Soluble in ethanol
Reversible acetylcholinesterase inhibitor
REVIEW Galantamine is a phenanthrene alkaloid and a reversible, competitive acetylcholinesterase inhibitor. It is not structurally related to other acetylcholinesterase inhibitors. Galantamine''s proposed mechanism of action involves the reversible inhibition of acetylcholinesterase, which prevents the hydrolysis of acetycholine, leading to an increased concentration of acetylcholine at cholinergic synapses. Galantamine also binds allosterically with nicotinic acetylcholine receptors and may possibly potentiate the action of agonists (such as acetylcholine) at these receptors.
Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer''s disease. Drugs. 2000 Nov;60(5):1095-122.
Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL: Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 1999 Dec 17;463(3):321-6.
Woodruff-Pak DS, Vogel RW 3rd, Wenk GL: Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):2089-94. Epub 2001 Feb 6.
Birks J: Cholinesterase inhibitors for Alzheimer''s disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Pubmed# Lilienfeld S: Galantamine-a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer''s disease. CNS Drug Rev. 2002 Summer;8(2):159-76.